NuVasive, Inc. (NUVA) Expected to Announce Earnings of $0.56 Per Share

Equities research analysts forecast that NuVasive, Inc. (NASDAQ:NUVA) will report earnings per share (EPS) of $0.56 for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for NuVasive’s earnings. The lowest EPS estimate is $0.55 and the highest is $0.56. NuVasive posted earnings per share of $0.53 during the same quarter last year, which suggests a positive year over year growth rate of 5.7%. The company is scheduled to announce its next earnings report on Thursday, February 8th.

On average, analysts expect that NuVasive will report full-year earnings of $1.91 per share for the current fiscal year, with EPS estimates ranging from $1.90 to $1.92. For the next financial year, analysts forecast that the company will report earnings of $2.35 per share, with EPS estimates ranging from $2.19 to $2.58. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover NuVasive.

NUVA has been the topic of a number of research reports. Royal Bank of Canada decreased their price target on shares of NuVasive from $75.00 to $70.00 and set an “outperform” rating on the stock in a research note on Friday, November 10th. Cowen set a $72.00 price target on shares of NuVasive and gave the company a “buy” rating in a research note on Thursday, October 12th. Robert W. Baird set a $60.00 price target on shares of NuVasive and gave the company a “hold” rating in a research note on Thursday, October 12th. Zacks Investment Research upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $70.00 price target on shares of NuVasive in a research note on Thursday, December 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $72.33.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Shelton Capital Management bought a new stake in NuVasive in the 2nd quarter valued at about $221,000. Zions Bancorporation bought a new stake in shares of NuVasive during the 3rd quarter worth approximately $160,000. Verition Fund Management LLC bought a new stake in shares of NuVasive during the 2nd quarter worth approximately $233,000. Icon Advisers Inc. Co. bought a new stake in shares of NuVasive during the 3rd quarter worth approximately $360,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of NuVasive during the 2nd quarter worth approximately $501,000.

Shares of NuVasive (NUVA) traded down $1.00 on Tuesday, reaching $47.40. 1,169,766 shares of the company were exchanged, compared to its average volume of 1,241,491. NuVasive has a twelve month low of $46.99 and a twelve month high of $81.68. The firm has a market cap of $2,440.00, a price-to-earnings ratio of 39.83, a P/E/G ratio of 1.39 and a beta of 0.50. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.51 and a current ratio of 2.85.

NuVasive announced that its board has initiated a share buyback plan on Tuesday, October 24th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the medical device company to buy shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/06/nuvasive-inc-nuva-expected-to-announce-earnings-of-0-56-per-share.html.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Get a free copy of the Zacks research report on NuVasive (NUVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply